Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPOSACONAZOLE (posaconazole) by Viatris (2) is 12. Approved for invasive aspergillosis in adults, older, invasive aspergillus and 4 more indications. First approved in 2023.
Drug data last refreshed 18h ago
12.1 Mechanism of Action Posaconazole is an azole antifungal agent [see ] . 12.2 Pharmacodynamics Exposure Response Relationship Treatment of Invasive Aspergillosis Across a range of posaconazole plasma minimum concentrations (C min , range: 244 to 5663 ng/mL) following administration of…
Worked on POSACONAZOLE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Azole Antifungal
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
Pharmacokinetic of Posaconazole in Critically Ill Patients
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo